Skyler JS,Bakris GL,Bonifacio E,Darsow T,Eckel RH,Groop L,Prognosis. Diabetes. L,Galaviz KI,Weber MB,Straus A,Haw JS,Narayan KMV,Ali MK,Care Glucose. Diabetes .2018 .Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and. , 10(7) : 2222-34.
Green A,Hede SM,Patterson CC,Wild SH,Imperatore G,Roglic G .2021 .Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia, 10(12) : 2741-50.
Saeedi P,Petersohn I,Salpea P,Malanda B,Karuranga S,Unwin N .2019 .Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract, 10 : 107843.
Forbes JM,Cooper ME JM .2013 .Mechanisms of diabetic complications. Physiol Rev, 10(1) : 137-88.
Fayfman M,Pasquel FJ,Umpierrez GE .2016 .Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am, 12(3) : 587-606.
Pfeiffer AF,Klein HH. .2014 .The treatment of type 2 diabetes. Dtsch Arztebl Int, 111(5) : 69-81.
Rodríguez-Gutiérrez R,Montori VM .2016 .Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes, 10(5) : 504-12.
Sherwani SI,Khan HA,Ekhzaimy A,Masood A,Sakharkar MK .2016 .Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights, 10 : 95-104.
Kirkman MS,Briscoe VJ,Clark N,Florez H,Haas LB,Halter JB .2012 .Diabetes in older adults. Diabetes Care, 10(12) : 1801-64.
Wei N,Zheng H,Nathan DM .2014 .Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care, 10(4) : 2173-51.
Raveendran AV,Chacko EC,Pappachan JM .2018 .Non-pharmacological Treatment Options in the Management of Diabetes Mellitus. Eur Endocrinol, 14(2) : 31-9.
Reichard P,Nilsson BY,Rosenqvist U. .1993 .The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med, 10(5) : 304-9.
Nathan DM,Bayless M,Cleary P,Genuth S,Gubitosi-Klug R,Lachin JM .2013 .Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes, 10(12) : 1093-86.
Brown RJ,Wijewickrama RC,Harlan DM,Rother KI .2010 .Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther, 10(4) : 457-60.
Pala L,Dicembrini I,Mannucci E. .2019 .Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol, 10(9) : 973-80.
Maruthur NM,Tseng E,Hutfless S,Wilson LM,Suarez-Cuervo C,Berger Z .2016 .Diabetes Medications as Monotherapy or MetforminBased Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med, 10(11) : 740-51.
Yerevanian A,Soukas AA .2019 .Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep, 10(2) : 156-64.
Zhang K,Yang W,Dai H .2020 .Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract, 10 : 108001.
van Dalem J,Brouwers MC,Stehouwer CD,Krings A,Leufkens HG,Driessen JH .2016 .Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ, 10 : .
Flory J,Lipska K .2019 .. , 10(19) : 1926-7.
Sola D,Rossi L,Schianca GP,Maffioli P,Bigliocca M,Mella R .2015 .Sulfonylureas and their use in clinical practice. Arch Med Sci, 10(4) : 840-8.
Tran KL,Park YI,Pandya S,Muliyil NJ,Jensen BD,Huynh K .2017 .Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits, 10(4) : 178-88.
Nauck MA,Kahle M,Baranov O,Deacon CF,Holst JJ .2017 .Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab, 10(2) : 200-7.
Zheng SL,Roddick AJ,Aghar-Jaffar R,Shun-Shin MJ,Francis D,Oliver N .2018 .Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA, 10(15) : 1580-91.
Brunton S. .2014 .GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. Int J Clin Pract, 10(5) : 557-67.
Richard KR,Shelburne JS,Kirk JK .2011 .Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther, 09(11) : 1609-29.
Lebovitz HE .2019 .Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep, 10(12) : 151.
Singh M,Kumar A .2018 .Risks Associated with SGLT2 Inhibitors: An Overview. Curr Drug Saf, 10(2) : 84-91.
Saisho Y. SGLT2 .2020 .Inhibitors: the Star in the Treatment of Type 2 Diabetes? Diseases. , 10(2) : 14.
Petznick A .2011 .Insulin management of type 2 diabetes mellitus. Am Fam Physician, 84(2) : 183-90.
Davies MJ,D'Alessio DA,Fradkin J,Kernan WN,Mathieu C,Mingrone G,Consensus A .2018 .Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 10(12) : 0033-701.
Howard-Thompson A,Khan M,Jones M,George CM .2018 .Type 2 Diabetes Mellitus: Outpatient Insulin Management. Am Fam Physician, 97(1) : 29-37.
Gagliardino JJ,Aschner P,Baik SH,Chan J,Chantelot JM,Ilkova H .2011 .Patients' education, and its impact on care outcomes, resource consumption and working conditions: data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab, 09(2) : 128-34.
Mingrone G,Panunzi S,De Gaetano A,Guidone C,Iaconelli A,Leccesi L .2012 .Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med, 10(17) : 1577-85.
Ilyas S,Al-Refai R,Maharjan R,Diaz Bustamante L,Ghattas KN,Khan S. Bariatric .2020 .Surgery and Type 2 Diabetes Mellitus: Assessing Factors Leading to Remission. A Systematic Review. Cureus, 10(8) : .
Capodanno D,Angiolillo DJ D .2016 .Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation, 10(20) : 1579-94.
American Diabetes .2021 .A. Standards of Medical Care in Diabetes-2021 Abridged for Primary Care Providers. Clin Diabetes, 10(1) : 14-43.